A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2011
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://ncbi.nlm.nih.gov/pubmed/22198412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1918-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars